1,298 results on '"Gonsalves, Wilson I."'
Search Results
2. Real-life sensitivity of flow cytometry minimal residual disease assessment for plasma cell neoplasms
3. Outcomes of patients with multiple myeloma refractory to standard dose vs low dose lenalidomide
4. Estimation of Kidney Function in Patients With Multiple Myeloma: Implications for Lenalidomide Dosing
5. An Open-Label Phase I Study of Metformin and Nelfinavir in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma
6. Long-term outcomes of allogeneic stem cell transplant in multiple myeloma
7. Utility of flow cytometry screening before MRD testing in multiple myeloma
8. Defining drug/drug class refractoriness vs lines of therapy in relapsed/refractory multiple myeloma
9. Impact of cytogenetic abnormalities on the risk of disease progression in solitary bone plasmacytomas
10. Daratumumab-lenalidomide and daratumumab-pomalidomide in relapsed lenalidomide-exposed or refractory multiple myeloma
11. Phase 1 Trial of MLN0128 (Sapanisertib) and CB-839 HCl (Telaglenastat) in Patients With Advanced NSCLC (NCI 10327): Rationale and Study Design
12. First relapse in patients with multiple myeloma: Outcomes and predictors.
13. Differences in the proteome within extracellular vesicles between premalignant and malignant plasma cell disorders
14. Simplified Risk Stratification Model for Patients With Waldenström Macroglobulinemia
15. Utility of PET/CT in assessing early treatment response in patients with newly diagnosed multiple myeloma
16. Mortality trends in multiple myeloma after the introduction of novel therapies in the United States
17. Success of the autologous stem cell boost after autologous graft failure in multiple myeloma and AL amyloidosis
18. Prognostic restaging after treatment initiation in patients with AL amyloidosis
19. Enzymatic activation of pyruvate kinase increases cytosolic oxaloacetate to inhibit the Warburg effect
20. Supportive care in multiple myeloma: Current practices and advances
21. Current diagnosis, risk stratification and treatment paradigms in newly diagnosed multiple myeloma
22. Bone marrow dendritic cell aggregates associate with systemic immune dysregulation in chronic myelomonocytic leukemia
23. Treatment and outcomes of patients with light chain amyloidosis who received a second line of therapy post autologous stem cell transplantation
24. Prognostic Role of Beta-2 Microglobulin in Patients with Light Chain Amyloidosis Treated with Autologous Stem Cell Transplantation
25. Utility of serum free light chain ratio in response definition in patients with multiple myeloma
26. Cytogenetic Features and Clinical Outcomes of Patients With Non-secretory Multiple Myeloma in the Era of Novel Agent Induction Therapy
27. Prognostic value of NT-ProBNP and troponin T in patients with light chain amyloidosis and kidney dysfunction undergoing autologous stem cell transplantation
28. Differences in engraftment with day-1 compared with day-2 melphalan prior to stem cell infusion in myeloma patients receiving autologous stem cell transplant
29. Revisiting complete response in light chain amyloidosis
30. IgM AL amyloidosis: delineating disease biology and outcomes with clinical, genomic and bone marrow morphological features
31. The impact of re-induction prior to salvage autologous stem cell transplantation in multiple myeloma
32. Autologous stem cell transplantation in patients with AL amyloidosis with impaired renal function
33. Outcomes of Patients with Light Chain Amyloidosis Who Had Autologous Stem Cell Transplantation with 3 or More Organs Involved
34. Deepening Responses after Upfront Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction Therapy
35. Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma
36. Treatment‐responsive glycogen storage myopathy in a patient with POEMS syndrome: A new monoclonal gammopathy‐associated myopathy
37. Immunoglobulin Deposition Diseases
38. Plasma Cell Leukemia
39. Baseline immune dysregulation in autologous stem cell transplant recipients is associated with a ‘graft versus host’-like syndrome and poor outcomes
40. Analysis of Clinical Factors and Outcomes Associated with Nonuse of Collected Peripheral Blood Stem Cells for Autologous Stem Cell Transplants in Transplant-Eligible Patients with Multiple Myeloma
41. Safety and efficacy of propylene glycol-free melphalan as conditioning in patients with AL amyloidosis undergoing stem cell transplantation
42. Impact of prior diagnosis of monoclonal gammopathy on outcomes in newly diagnosed multiple myeloma
43. Prognostic restaging at the time of second-line therapy in patients with AL amyloidosis
44. Relapse after complete response in newly diagnosed multiple myeloma: implications of duration of response and patterns of relapse
45. Correlation between urine ACR and 24-h proteinuria in a real-world cohort of systemic AL amyloidosis patients
46. In vivo assessment of glutamine anaplerosis into the TCA cycle in human pre-malignant and malignant clonal plasma cells
47. Failure of mobilization of hematopoietic stem cells associated with elevated serum levels of anti‐CD38 monoclonal antibody
48. Cryoglobulins and Cryoglobulinemia
49. Delineation of the timing of second-line therapy post–autologous stem cell transplant in patients with AL amyloidosis
50. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.